Data from a retrospective multicenter study, along with a review of previous trials, supported the real-world utility of ...

In clinical trials, new medications such as upadacitinib and dupilumab have shown promising results for patients with moderate to severe atopic dermatitis. Upadacitinib, an oral Janus kinase ...

for atopic dermatitis (also known as eczema), ulcerative colitis, Crohn's disease, and rheumatoid arthritis. Geraldine MacGibbon, Pharmac’s Director Pharmaceuticals, says “our team have used ...

Recent developments in the field include an evolving treatment landscape and the development of evidence-based guidelines.

The drug is also being studied in other immune-mediated diseases – phase 3 trials of upadacitinib in atopic dermatitis, psoriatic arthritis, Crohn's disease, and ulcerative colitis are ongoing ...

and AbbVie's Rinvoq (upadacitinib) – which are currently waiting for FDA decisions on extending their use into atopic dermatitis. Pfizer's Xeljanz follow-up Cibinqo (abrocitinib) was approved ...

AA often co-occurs with atopic dermatitis (AD). Both conditions are difficult to ... inhibitors (baricitinib, abrocitinib, upadacitinib), with only baricitinib being approved by the Food and Drug ...

Atopic dermatitis is a chronic inflammatory skin disease affecting a growing number of people worldwide. Marked by persistent ...

Self-reported manifestations of topical steroid withdrawal in atopic dermatitis include erythema, desquamation, dryness, and oozing.

AD, The most common inflammatory skin disorder worldwide, is a highly heterogeneous condition with current treatments that do ...